The PreCISe results reinforce the importance and clinical benefit of early treatment initiation. Early treatment with disease-modifying therapies, such as COPAXONE®, is recommended by the National MS Society to prevent or delay the initiation or progression of irreversible neuronal damage. In the PreCISe study, investigators found:
· A 45 percent reduction in the risk of developing clinically definite MS in patients treated with COPAXONE® compared to those taking placebo; and,
· 25 percent of the patients treated with COPAXONE® delayed conversion to clinically definite MS by 115 percent (from 336 days for placebo to 722 days for COPAXONE®.)
Based upon those results, earlier this year, the FDA approved an expanded label for COPAXONE® to include the treatment of patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. Similar indications were also approved in the EU, Australia and Canada.
Lancet PreCISe Commentary Piece: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61453-7/fulltext